Patents Examined by Rebecca E. Prouty
  • Patent number: 10927339
    Abstract: The present disclosure provides a new mutant of Bacillus thuringiensis which is deposited under Accession number DSM 32419. The present disclosure also provides a method for manufacturing a growth promoter for promoting microalgal cell growth, including: (a) inoculating a mutant of Bacillus thuringiensis into a culturing medium to obtain a bacterial suspension, wherein the mutant of Bacillus thuringiensis is deposited under Accession number DSM 32419; (b) culturing the mutant of Bacillus thuringiensis in the bacterial suspension at least to a stationary phase to obtain a cultured medium of the mutant of Bacillus thuringiensis; and (c) performing a vacuum heating procedure on the cultured medium of the mutant of Bacillus thuringiensis to obtain the growth promoter for promoting microalgal cell growth, wherein the growth promoter for promoting microalgal cell growth contains active substances for promoting microalgal cell growth.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 23, 2021
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chang-Chieh Chen, Ming-Der Bai, Shao-I Wu, Hsin-Tzu Kuo, Wen-Chang Lu, Hou-Peng Wan
  • Patent number: 10920252
    Abstract: It has been found that esterification of a hydroxy-fatty acid by a lipase can be coupled with oleate hydratase (OHase) generation of that hydroxy-FA from an unsaturated FA with a cis C9-C10 double bond, e.g. oleic acid, in a single aqueous buffered reaction medium at low temperature, e.g. 30° C. A simple one-pot enzymatic method to produce fatty acid estolides from one or more triglycerides, e.g. starting from a natural plant oil, is thereby enabled in which the same lipase catalyses both the initial hydrolysis of triglyceride and the final esterification step.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: February 16, 2021
    Assignee: Stichling Wageningen Research; Technische Universiteit Delft
    Inventors: Carmen Gabriela Boeriu, Anamaria Todea, Isabella Wilhelmina Christina Everdina Arends, Ludwina Gerharda Otten
  • Patent number: 10889835
    Abstract: This invention provides compositions and methods for providing high product yield of transgenes expressed in cyanobacteria and microalgae.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 12, 2021
    Assignee: The Regents of the University of California
    Inventors: Anastasios Melis, Cinzia Formighieri
  • Patent number: 10883123
    Abstract: An integrated wet-mill method for the production of ethanol and single cell protein. An integrated method for the production of ethanol and a single cell protein product is described including providing corn kernels, which kernels comprise germ, fiber, protein and starch and which method includes, among other things, steeping said corn kernels and separating said steeped kernels from a steep liquor.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 5, 2021
    Assignee: White Dog Labs, Inc.
    Inventors: Bryan P. Tracy, Shawn William Jones, John Randall Phillips, Daniel Knox Mitchell, Aharon M. Eyal
  • Patent number: 10876099
    Abstract: The present invention relates to preparation and application of a cyclodextrin glucosyltransferase mutant, belonging to the fields of gene engineering and enzyme engineering. By mutating amino acids of cyclodextrin glucosyltransferase, the enzyme activity of the obtained mutant can reach 2.5 times that of wild enzyme. In addition, the cyclodextrin glucosyltransferase mutant obtained in the present invention is simple in purification and suitable for industrial production.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 29, 2020
    Assignee: Jiangnan University
    Inventors: Jing Wu, Lingqia Su, Xiumei Tao, Yusheng Wang, Junchen Dong
  • Patent number: 10858677
    Abstract: A novel method of producing 3-hydroxyadipic acid using a metabolic pathway of a microorganism is disclosed.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: December 8, 2020
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Kyohei Isobe, Kenji Kawamura, Masateru Ito, Katsushige Yamada
  • Patent number: 10851352
    Abstract: The present invention discloses a Mycobacterium neoaurum-derived steroid C27-monooxygenase and an application thereof, which belong to the technical fields of genetic engineering and enzyme engineering. By the method of gene knockout and intensive expression, the present invention screens out three isoenzymes of a key enzyme SMO in the process of degrading sterol side chains from Mycobacterium neoaurum. The three isoenzymes are intensively expressed respectively in the Mycobacterium neoaurum for the high yield of androsta-1,4-diene-3,17-dione (ADD), the yield of ADD is increased remarkably, wherein the effect of SMO2 is most remarkable. By overexpressing SMO2, the final ADD yield is increased from 5.2 g·L?1 to 7.3 g·L?1. The present invention provides a helpful guidance for the industrialization of the microbial fermentation method for increasing the ADD yield.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: December 1, 2020
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Zhiming Rao, Minglong Shao, Xian Zhang, Taowei Yang, Meijuan Xu
  • Patent number: 10844359
    Abstract: The present disclosure relates to a novel acetohydroxy acid synthase, a microorganism comprising the same, or a method for producing an L-branched-chain amino acid using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: November 24, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Ae Ji Jeon, Byeong Cheol Song, Ji Hye Lee, Jong Hyun Kim, Hye Won Kim
  • Patent number: 10837030
    Abstract: The invention relates to a method for propagating yeast, for use in the production of a fermentation product from lignocellulosic biomass, including the steps that consist of: a. providing a reactor; b. placing in contact in said reactor: a population of yeasts capable of metabolising pentoses and hexoses, with 0.2 to 2.0 g of yeast solids per kg of prepared complete medium, raw marc from the pretreatment of the lignocellulosic biomass, with a solids content (MS) of 8% to 15%, nutrients, and cellulases, with 5 to 15 mg of proteins per gram of MS; and c. incubating the mixture at a temperature of 25° C. to 38° C., preferably 28° C. to 33° C., in microaerobiosis, in which the saccharification of the raw marc and the growth of the yeast are carried out simultaneously.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: November 17, 2020
    Assignees: LESAFFRE ET COMPAGNIE, AGRO INDUSTRIE RECHERCHES ET DEVELOPPEMENTS A.R.D., INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE INRA
    Inventor: Flora Ghisoni
  • Patent number: 10837031
    Abstract: The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 17, 2020
    Assignee: BAYMEDICA, INC.
    Inventors: Philip J. Barr, Charles K. Marlowe, Jianping Sun
  • Patent number: 10822627
    Abstract: The present invention relates to a hydantoinase having an amino acid sequence selected from (i) or (ii), with (i) amino acid sequence selected from SEQ ID NO: 6-20 and SEQ ID NO: 73-119 (ii) amino acid sequence wherein in the amino acid sequence of SEQ ID NO: 6-20 and SEQ ID NO: 73-119, 1 to 75 amino acid residues have been substituted, deleted, inserted and/or added, and wherein further the catalytic activity of the hydantoinase is higher by a factor of at least 1.2 than the catalytic activity of the hydantoinase having amino acid sequence SEQ ID NO: 1. The present invention further relates to a process for preparing amino acids, wherein said hydantoinase is used.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 3, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Steffen Osswald, Heiko Schuster, Jurgen Roos, Andreas Karau, Ulrich Schwaneberg, Ronny Martinez, Hemanshu Mundhada, Ursula Holter
  • Patent number: 10822594
    Abstract: A method for the enzymatic conversion of a phenol substrate into a corresponding catechol product comprises the step of incubating the phenol substrate with a Ralstonia solanacearum tyrosinase enzyme, or a functional derivative thereof, in a reaction mixture, for a period of time sufficient to allow the enzyme convert at least some of the phenol substrate into the catechol product.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 3, 2020
    Assignee: University College Dublin, National University of Ireland, Dublin
    Inventors: Kevin O'Connor, Susan Molloy, Reeta Davis, Wesley Shaw
  • Patent number: 10815511
    Abstract: The invention provides compositions and methods for engineering bacteria to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: October 27, 2020
    Assignee: Glycosyn LLC
    Inventors: Massimo Merighi, John M. McCoy, Matthew Ian Heidtman
  • Patent number: 10793828
    Abstract: Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-vesicle from the cell, wherein the micro-vesicle includes the target protein. Also provided are cells, reagents and kits that find use in making the micro-vesicles, as well as methods of using the micro-vesicles, e.g., in research and therapeutic applications.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: October 6, 2020
    Assignee: Takara Bio USA, Inc.
    Inventors: Michael Haugwitz, Thomas Patrick Quinn, Andrew Alan Farmer, Montserrat Morell Fernández
  • Patent number: 10751384
    Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to one or more of SEQ ID No(s) 1, 2, 3 or 4. The therapeutically effective amount of polypeptide may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed are methods for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide according to SEQ ID Nos. 1-4.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 25, 2020
    Assignee: IMAGINE PHARMA LLC
    Inventors: Ngoc Thai, Jonathan Pollett
  • Patent number: 10731193
    Abstract: The invention relates to a genetically modified microorganism for making a recombinant oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source. The one or more genes encoding a sucrose utilization system are preferably one or more genes encoding a heterologous PTS-dependent sucrose utilization transport system, such as the scr genes.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 4, 2020
    Assignee: GLYCOM A/S
    Inventors: Eric Samain, Pauline Peltier-Pain, Katrine Bych, Ted Johanson, Elise Champion, Gyula Dekany
  • Patent number: 10676765
    Abstract: Described is a method for the conversion of 3-methylcrotonyl-CoA into 3-hydroxy-3-methylbutyric acid comprising the steps of: (a) enzymatically converting 3-methylcrotonyl-CoA into 3-hydroxy-3-methylbutyryl-CoA; and (b) further enzymatically converting the thus produced 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyric acid wherein the enzymatic conversion of 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyric acid according to step (b) is achieved by first converting 3-hydroxy-3-methylbutyryl-CoA into 3-hydroxy-3-methylbutyryl phosphate and then subsequently converting the thus produced 3-hydroxy-3-methylbutyryl phosphate into 3-hydroxy-3-methylbutyric acid.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: June 9, 2020
    Assignee: Global Bioenergies
    Inventors: Philippe Marlière, Maria Anissimova, Mathieu Allard
  • Patent number: 10662446
    Abstract: Disclosed herein are new strains of Propionibacterium and methods for the biosynthetic production of propionic acid.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: May 26, 2020
    Assignee: The University of Queensland
    Inventors: Carlos H. Luna-Flores, Lars K. Nielsen, Esteban Marcellin, Christopher C. Stowers, Bianca F. Martins, Brad M. Cox
  • Patent number: 10647947
    Abstract: The present invention concerns a detergent comprising a polypeptide having galactanase activity. It further concerns a laundering method and the use of galactanases. The present invention further relates to polypeptides having galactanase activity, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: May 12, 2020
    Assignee: Novozymes A/S
    Inventors: Lilian Eva Tang Baltsen, Kirk Matthew Schnorr, Klaus Gori, Lars Kobberoe Skov
  • Patent number: 10639356
    Abstract: The present invention provides, among other things, effective treatment for Sanfilippo Syndrome Type A (MPS IIIA) based on intrathecal delivery of recombinant heparan N-sulfatase (HNS) enzyme. The present invention also includes methods of treating Sanfilippo Syndrome Type A (MPS IIIA) Syndrome by intrathecal administration of a recombinant HNS enzyme at a therapeutically effective dose and an administration interval for a period sufficient to decrease glycosaminoglycan (GAG) heparan sulfate level in the cerebrospinal fluid (CSF) relative to baseline (e.g., prior to treatment) as well as to improve, stabilize, or reduce decline of cognitive function, disability, behavior, quality of life and/or auditory brainstem response relative to baseline (e.g., prior to treatment).
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 5, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Patrick Anthony John Haslett